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Transcriptomic phases 
of periodontitis lesions using 
the nonhuman primate model
Jeffrey L. Ebersole1,3*, Radhakrishnan Nagarajan2, Sreenatha Kirakodu3 & 
Octavio A. Gonzalez3,4
We used a nonhuman primate model of ligature-induced periodontitis to identify patterns of gingival 
transcriptomic after changes demarcating phases of periodontitis lesions (initiation, progression, 
resolution). A total of 18 adult Macaca mulatta (12–22 years) had ligatures placed (premolar, 1st molar 
teeth) in all 4 quadrants. Gingival tissue samples were obtained (baseline, 2 weeks, 1 and 3 months 
during periodontitis and at 5 months resolution). Gene expression was analyzed by microarray [Rhesus 
Gene 1.0 ST Array (Affymetrix)]. Compared to baseline, a large array of genes were significantly 
altered at initiation (n = 6049), early progression (n = 4893), and late progression (n = 5078) of disease, 
with the preponderance being up-regulated. Additionally, 1918 genes were altered in expression 
with disease resolution, skewed towards down-regulation. Assessment of the genes demonstrated 
specific profiles of epithelial, bone/connective tissue, apoptosis/autophagy, metabolism, regulatory, 
immune, and inflammatory responses that were related to health, stages of disease, and tissues with 
resolved lesions. Unique transcriptomic profiles occured during the kinetics of the periodontitis lesion 
exacerbation and remission. We delineated phase specific gene expression profiles of the disease 
lesion. Detection of these gene products in gingival crevicular fluid samples from human disease may 
contribute to a better understanding of the biological dynamics of the disease to improve patient 
management.
Periodontal diseases are chronic dysregulated responses to dysbiotic  microbiomes1–3. However, the literature is 
sparse regarding the earliest changes that occur in the local microbiome at sites that will transition from health 
to periodontal lesions. Furthermore, the disease is expressed temporally as exacerbations and remissions with 
the frequency and magnitude of the episodes explaining the variation in disease extent/severity across the 
 population4,5. This episodic disease can occur at one or multiple sites sequentially or concomitantly, and appears 
to occur with greater incidence at sites that have already demonstrated a previous disease  process6–8.
A challenge in the field is that sampling of humans for the comprehensive biology of the disease process 
remains somewhat problematic for detailing the dynamics of an episodic disease. The experimental designs 
are generally limited to a point-in-time with clinical definition of health or disease at that point. While human 
disease can be clinically monitored over time at multiple sites per tooth and across the dentition, the inability to 
sample site-specific tissues on multiple occasions, makes the assessment of the biology of the tissues representing 
differences in phases of initiation, progression, stabilization, or resolution of the disease lesion at a particular site 
challenging. Additionally, while investigations of periodontitis in rodents and  rabbits9,10 clearly can provide useful 
information regarding the underlying biology of local and systemic host responses, the autochthonous complex 
microbiomes are completely different in these species versus humans, and the major oral pathogens in human 
disease have no tropism for colonizing rodents and  rabbits11–13. Thus, we and others have employed a nonhuman 
primate model of periodontal disease over the last nearly 40 years. It has been shown that the microbiology, 
immunology, and clinical expression of periodontitis are quite similar in humans and nonhuman primates, 
including naturally-occurring disease that increases with  aging14–16. We have also recently reported a familial 
relationship of periodontitis susceptibility and resistance in multigenerational matrilines of Macaca mulatta14 
consistent with some heritability/genetic contribution to the disease, as has been described in  humans17–19.
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Thus, this report describes longitudinal studies of biological processes of periodontitis using a nonhuman pri-
mate model of ligature-induced disease. Gene expression profiles were determined in gingival tissues with health 
and during initiation, progression, and resolution of periodontitis, reflecting the episodic nature of the disease in 
humans. The hypothesis tested was that there would be unique gene expression profiles that discriminate phases 
of periodontitis. The findings would shed some light into the temporal nature of changes in biological factors/
pathways through the disease process. This would provide the potential for identifying targeted biomolecules 
that could be used to better characterize disease sites in humans, and identify differences in the biological char-
acteristics of healthy (never diseased) sites from previously diseased sites that have been successfully treated, as 
potential biomarkers of future risk for disease.
Results
Dynamics of periodontitis lesions. Figure 1 provides a schematic model of periodontitis as suggested 
from human studies of exacerbation and remission of clinical features of disease. It is well recognized that peri-
odontitis is generally not expressed until about the 3rd–4th decade of life, even though the host response system 
and oral microbiome are interacting during a 30 + year time period prior to  disease20–22. Existing data support 
that many or most of the bacteria generally associated with periodontitis are also present in younger individu-
als, who often demonstrate substantial gingival inflammation, but do not appear to transition to destructive 
 disease23–27. Additionally, numerous reports have suggested a genetic contribution to disease related to gene 
polymorphisms that would exist from the beginning of life in at-risk  individuals17. Thus, the “risk microbiome’ 
and “risk genetic predisposition” occur for decades prior to clinical disease expression. At some point within an 
individual at one or more sites a disease process is initiated. Based upon the biology of how a host reacts to a 
bacterial challenge, this initial insult would likely last for days or weeks, either resolving rapidly or transiting to 
progressing disease. It is unknown regarding the temporal linkage of the biological changes with detectable clini-
cal disease, but it would be predicted that this interaction occurs with disease progression over weeks to months 
based upon rodent and nonhuman primate experimental  data9,10,28. While once clinical tissue destruction has 
occurred, it is irreversible, human studies would support that the disease can and does resolve biologically, limit-
ing the extent of  destruction4,29,30. With a particular disease lesion, this now stabilized site may exist for weeks 
or even years; however, human studies support that the greatest predictor of formation of a periodontal lesion is 
past disease at the same  site5,31. Nevertheless, there is minimal guidance regarding the biology of resolved sites 
relative to future disease exacerbations. Thus, we implemented a study to examine this temporal nature of the 
disease process in nonhuman primates, focusing on gingival gene expression profiles to identify unique biologic 
processes occurring at the different stages of disease.
Figure 2 summarizes the clinical presentation of ligated teeth for bleeding on probing and probing pocket 
depth. Consistent with previous studies, inflammation and tissue destructive changes occurred rather rapidly 









































Figure 1.  Model of exacerbations and remission of periodontal disease lesions. Graph reflects inherent risk due 
to genetic predisposition and existing oral microbiome characteristics. Biologic changes occur with initiation 
and progression of disease the generally presage the clinical changes measured. The model indicates that the 
biological parameters of disease stabilize and decrease during disease remission and resolution. However, the 
clinical features of lost epithelial attachment, connective tissue destruction and alveolar bone resorption remain 
as markers of the previous disease process.
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the ligatures after sampling at 3 months resulted in a general clinical resolution of these disease features that 
approximated the baseline health values.
Gene expression profiles in periodontitis lesions. A detailed examination (Table 1) showed a sub-
stantial number of genes with significant differences from baseline samples. These included genes that were both 
up- and down-regulated at ≥ 1.5-fold with disease initiation and progression. Interestingly, while there was a 
large number of genes that were significantly different between disease resolution and baseline, only about 400 
demonstrated this fold-level of differential expression.
Since a goal was to identify genes that were uniquely expressed at each time point, the plots in Fig. 3 provide 
the features of expression for subsets of the genes for baseline expression compared to the other time points. 
As shown, 358, 330, 271, and 80 genes at 0.5, 1, 3 and 5 months, respectively that fulfilled the threshold of ≥ 1.5 
difference between baseline and any other time point. Of interest was that during disease these genes were up-
regulated, while at resolution the distinctive genes were expressed at a lower-level than baseline. Figure 3c depicts 
a similar analysis of gene expression during disease initiation, progression and resolution compared to all other 
phases. This differential expression showed a limited number of genes (n = 20) and (n = 24) that were distinct at 
0.5 and 1 month, respectively. At 3 months (late progression), 68 genes showed increased or decreased expres-
sion by > twofold. As noted with the baseline comparison the primary effects on gene expression with resolution 
was a profile of significantly (p < 0.05) decreased expression of genes (n = 18) compared to the other time points.
Functional characteristics of gene expression of periodontitis lesions. The next step in the pro-
cess was to identify those genes/pathways that provided unique signatures for baseline healthy tissues, tissues 
Figure 2.  Clinical features of inflammation (bleeding on probing, BOP) and destructive disease (probing 
pocket depth, PPD) in ligated sites of the nonhuman primates. Ligatures were removed after clinical measures 
at 3 months, with 5 month samples representing clinical resolution. The points denote the mean values from 18 
animals and the vertical brackets enclose 1 SD.
Table 1.  Distribution of altered gene expression in gingival tissues during ligature-induced periodontitis and 
at disease resolution compared to baseline healthy tissues.
Sample (mo.) Stage
P-value < 0.01 Gene expression changes (#)
Total# UP (Fold ≥ 1.5) DOWN (Fold ≥ 1.5)
0.5 Initiation 6049 943 472
1 Early progression 4893 692 471
3 Late progression 5078 542 372
5 Resolution 1918 176 221
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Figure 3.  (A) Patterns of gene expression with disease and resolution compared to baseline/health. (B) Patterns 
of gene expression in baseline/health versus all other time points. (C) Patterns of gene expression with disease 
and resolution compared all other time points in the model. Numbers in parentheses denote number of genes 
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from sites with initiation and progression of disease, and tissue samples from clinically resolved lesions. Figure 4 
summarizes the functional categories of the genes that were increased or decreased by > twofold at each of the 
phases compared to baseline healthy tissues. Numerous genes related to epithelial cell biology were affected 
as early as 2 weeks (Initiation) and remained different from health throughout lesion progression and even in 
resolution tissues. Inflammation genes were overly represented at disease initiation; decreasing in number with 
disease progression. Additionally, cellular metabolic and regulatory genes were affected rapidly at disease initia-
tion and early progression and decreased in representation in late progression and resolution. Finally, adaptive 
immune genes were highly represented in early and late disease progression, with many remaining altered even 
in resolution samples. Table 2 provides a summary of the gene expression profile functions that were phase-
related across health, disease and resolution samples. In healthy tissues, epithelial cell, metabolic, and regulatory 
genes generally were elevated and down-regulated with disease. In contrast, genes related to adaptive immune 
responses were expressed at low levels in healthy tissues and increased significantly in prevalence with dis-
ease. With disease initiation, the number of inflammatory genes were substantially increased as were changes in 
additional genes related to epithelial cell functions and integrity of the epithelium. Early progression showed a 
more limited number of genes that were differentially expressed (> twofold) compared to all other time points, 
primarily for epithelial cell genes (decreased) and adaptive immune genes (increased). A distinctive gene profile 
was observed during late progression, with 96% of the phase specific genes associated with adaptive immune 
responses. Finally, in resolution samples, a low number of unique differentially expressed genes was observed 
with expression of primarily inflammation-associated genes remaining elevated.
A listing of genes that specifically hallmarked healthy gingival tissues from the stages of disease or resolved 
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significantly elevated levels in healthy tissues and decreased with onset of disease. In contrast, cellular metabo-
lism, regulatory, and inflammation/immune genes were increased with disease onset and progression. Table 3 
also provides a similar summary identification of 45 genes that hallmarked disease initiation/early progression 
of the lesion. These genes were generally up-regulated during these stages of disease and were represented by 
a broad mix of functions, generally significantly increased over baseline healthy levels. Examination of unique 
phase specific gene expression profiles during late progression of disease identified 45 altered transcript signals 
(Table 3). These were skewed towards genes related in inflammation and immune responses. As with gene 
expression at initiation/early progression, these identified genes were increased compared to baseline sam-
ples. However, the most prominent markers comprising > 50% of the up-regulated genes were associated with 
immunoglobulin formation and antibody recombination processes of adaptive immune responses. Finally, we 
identified gene differences (n = 33) in baseline healthy sites versus sites that appeared clinically healthy post-
resolution of a disease process (Table 3). Of note was that a number of these genes were decreased from health 
with disease and continued at a lower level of expression in the resolution samples, albeit, at levels improved over 
the disease samples (e.g. keratins, LIPM). MUC4 was unique in that it was increased with disease, but increased 
to even greater levels once the disease had resolved. In contrast, EGR1 was decreased with disease from health 
and was down-regulated even more in resolution samples. Additionally, some genes, e.g. CD36, PTGS2 genes 
were decreased only in resolved disease tissues versus health or disease. No differences were noted in these gene 
expression profiles based on sex of the animals. While not included in the table, an observation was that of the 
array of Ig genes of adaptive immunity that were significantly elevated in late progression, remained elevated in 
resolution compared to healthy tissue samples.
Discrimination of gingival tissues in health and disease. We then evaluated the capacity of these 
subsets of differentially expressed genes to discriminate the various stages of health and disease in the gingi-
val samples. A principal components analysis (Fig.  5) summarizes the results. These Principal Components 
accounted for 62% of the variation in the samples derived from the various time points. As noted the baseline 
healthy samples and disease initiation (0.5 months) samples demonstrated the greatest discrimination. Also, the 
distribution of resolution samples suggests a subset that overlapped with healthy patterns, and a second subset 
appeared more similar to the expression profiles for late progression (3 months). Finally, the early progression 
samples showed some separation from the other disease points, although the individual variation and overlap 
with both initiation and/or late progression, supported the limited number of unique gene patterns for the 
1 month time point.
Classification of phases of periodontitis lesions using gene expression profiles. Finally, using a 
set of 67 genes, based upon differential expression at one or more of the timepoints, we created a flow chart to 
determine expression levels of each of these genes related to discriminating the phase of disease (Supplementary 
Fig. S1). From this measure, we determined threshold values for the ratios that were distinctive for the healthy 
and disease phase samples. We then determined for each sample, the number of expression values for individual 
gingival samples that fell above or below the threshold. This resulted in 4 different gene clusters (I-IV) repre-
sented by 20, 12, 16 and 18 genes respectively (Table 4). Additionally, subgrouping the Cluster I genes into IA and 
IB with a different threshold (Table 4) was effective in differentiating the baseline healthy samples to those tissues 
with clinically resolved lesions. Figure 6 provides a summary of the 18 specimens collected at each of the 5 time 
points. As noted Clusters I-IV identified health from disease with 15/18 health and only 3/18 were misclassi-
fied. Cluster II-IV gene response profiles accurately categorized 15/18 samples at disease initiation (2 weeks) 
and 17/18 samples at the time of late disease progression (3 months). Of interest was using these 3 clusters of 
responses, the early progressing lesions demonstrated a very mixed pattern of responses with 2 samples classified 
with health, 4 samples classified with initiation, 9 samples classified with early progression, and 3 classified with 
late progression specimens. The results suggest that the early progression of the lesion appears to vary biologi-
cally across the individual animals in response to the ligature challenge. Figure 6 also demonstrates the ability of 
the response profile of genes in Cluster IA and IB to classify what appears to be a different biology of the baseline 
healthy samples to those from teeth that had lesions that had clinically resolved. Using the adjusted thresholds, 
13/18 healthy and 11/18 resolution samples were accurately classified.
Discussion
Critical features of the underlying biological processes that occur during the transition from periodontal health to 
disease remain elusive. It is clear that accompanying the clinical changes that hallmark this site specific mucosal 
disease, numerous biomarkers of inflammation and altered innate and adaptive immune response parameters 
can be detected in the subgingival sulcus via gingival crevicular  fluid32–35, and even in whole  saliva36–38 reflecting 
these local changes. While an array of reports using rodent models of disease have attempted to document the 
various host response components that contribute to the clinical changes, these models are limited by a lack of 
any similarity to the oral microbiome in human disease. Moreover, they generally use a biased host response 
assessment focusing on individual or a finite array of factors of interest. Papapanou and  colleagues39–41 have 
reported a range of studies of human gingival tissue transcriptomes comparing chronic to aggressive disease, 
and attempting to identify crucial pathways and transcription factors that associate with existing disease. An 
observation from these data was the extensive heterogeneity in expression of genes in diseased tissues generally 
attributed to individual variation in host response genetics and the individual’s oral microbiome. However, this 
report describes an additional alternative for the variation in the human transcriptome profiles, that is, the human 
samples are obtained at a point-in-time and classified by clinical measures that could have occurred weeks/
months previously, could reflect ongoing progression, or could be a disease stable site only presenting a history 
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of a disease process. Thus, we employed a monkey model of ligature-induced disease by which we can directly 
identify initiation, progression, and resolution of periodontal lesions that would be difficult to accomplish in 
the human disease model.
This experimental model enabled us to identify transcriptomes in the gingival tissues derived from different 
phases of the disease process. The goal of detailing the transcriptome would be to document arrays of genes 
with elevated or depressed expression that discriminated healthy tissues, as well as initiation and progression of 
Figure 4.  Depiction of the array of genes in various functional categories that differed by ≥ twofold at health 
versus other sampling points. Pie charts denote the proportions of each functional category of genes that 
comprised the overall number of genes (in parentheses) that were differentially expressed.
Table 2.  Identification of altered gene expression in gingival tissues, with functional patterns unique to each 
phase of health, disease and resolution by comparison to gene expression profiles in all other phases of lesion 
formation and resolution. Value denote number of genes represented in each category. Fxn denotes functional 
categorization of genes: Epi epithelium, Conn connective tissue, Bone, Meta metabolic, Regul regulatory, Inflam 




Epi Meta Regul Inflam Imm Adap Conn Vasc Auto Apop Bone Pseudo
Health/BL 163 45 21 13 10 13 49 6 2 2 0 0 1
Initiation/2 wks 70 13 7 8 23 1 3 7 5 0 0 0 0
Early progression/1 mo 20 10 0 1 1 0 7 1 0 0 0 0 0
Late progression/3 mo 50 0 0 1 1 0 48 0 0 0 0 0 0
Resolution/5 mo 17 1 1 2 10 0 0 2 1 0 0 0 0
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Gene ID FXN Ontology
Health versus disease
ANAX3 Conn Annexin A3
DRAM1 Conn DNA damage regulated autophagy modulator 1
MMP1 Conn Matrix metalloproteinase 1
PXDN Conn Peroxidasin
SERPINE2 Conn Serpin family E member 2
TFPI Conn Tissue factor pathway inhibitor
ALOXE3 Epi Arachidonate lipoxygenase 3
ALOX12B Epi Arachidonate 12-lipoxygenase, 12R type
CDSN Epi Corneodesmosin
CRNN Epi Cornulin
DSC1 Epi Desmocolin 1
KLK5 Epi Kallikrein related peptidase 5
KRT1 Epi Keratin 1
KRT2B Epi Keratin, type II cytoskeletal 2 oral-like
LCE3C Epi Late cornified envelope 3C
NID1 Epi Nidogen 1
ODAM Epi Odontogenic, ameloblast associated
PRR9 Epi Proline rich 9
RPTN Epi Repetin
SERPINB13 Epi Serpin family B member 13
SPINK9 Epi Serine peptidase Inhibitor, Kazal Type 9
BPIL2/BPILFC Imm Bactericidal/permeability increasing protein-like 2
SIRPB1 Imm Signal regulatory proten beta 1
SLAMF6 Imm SLAM family member 6
WFDC12 Imm WAP four-disulfide core domain 12
CD177 Inflam CD177 molecule
CSF3R Inflam Colony stimulating factor 3 receptor (granulocyte)
CXCL8 Inflam Interleukin 8
CXCL6 Inflam Chemokine (C-X-C motif) ligand 6
GSDMA Inflam Gasdermin A
HPGD Inflam 15-Hydroxyprostaglandin dehydrogenase
IL36B/IL1F8 Inflam Interleukin 36 beta
SERPINB5 Inflam Serpin family B member 5
TNFRSF19 Inflam TNF receptor superfamily member 19
AADAC Metab Arylacetamide deacetylase
AKR1C3 Metab Aldo–keto reductase family 1 member C3
ALAS2 Metab 5′-aminolevulinate synthase 2
ARSF Metab Arylsulfatase F
ESYT3 Metab Extended Synaptotagmin 3
SERPINA3 Metab Serpin family A member 3
TDH Metab L-threonine dehydrogenase (pseudogene)
FAM178B Regul Family with sequence similarity 178 member B
RNU6-1 Regul U6 spliceosome
Initiation/early progression
BLK Adap BLK proto-oncogene, Src family tyrosine kinase
IGKV1-ACY*02 Adap Immunoglobulin kappa variable 1 ACY*02
IGKV1S14*01 Adap Immunoglobulin kappa variable 1S14*01
IGKV3-ACF*02 Adap Immunoglobulin kappa variable 3 ACF*02
IGLV2S9*01 Adap Immunoglobulin lambda variable 2S-9*01
MZB1 Adap Marginal zone B and B1 cell specific protein
MUC4 Auto Mucin 4, cell surface associated
NAIP Auto NLR family apoptosis inhibitory protein
RUBCNL Auto Rubicon like autophagy enhancer
ACTA2 Epi Actin alpha 2, smooth muscle
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Gene ID FXN Ontology
KRT8 Epi Keratin 8
KRT15 Epi Keratin 15
NID2 Epi Nidogen 2 (osteonidogen)
PLIN2/ADFP Epi Perilipin 2
COL4A2 Conn Collagen type IV alpha 2
ESM1 Conn Endothelial cell-specific molecule 1
HAS2 Conn Hyaluronan synthase 2
PLAU Conn Plasminogen activator, urokinase
PLAT Conn Plasminogen activator, tissue type
ADAMTS9 Metab ADAM metallopeptidase with thrombospondin type 1 motif 9
CTSL Metab Cathepsin L
CYP4F3 Metab Cytochrome P450 family 4 subfamily F member 3
NOX4 Metab NADPH oxidase 4
MTHFS Metab Methenyltetrahydrofolate synthetase
MSMO1 Metab Methylsterol monooxygenase 1
SLC11A1 Metab Solute carrier family 11 member 1
SULF1 Metab Sulfatase 1
TGM2 Metab Transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)
IL1B Inflam Interleukin 1 beta
MIR223 Inflam microrna 223
NLRP12 Inflam NLR family pyrin domain containing 12
SELL Inflam Selectin L
TLR2 Imm TOLL like receptor 2
TLR4 Imm Toll-like receptor 4
IL33 Imm Interleukin 33
LILRA2 Imm Leukocyte immunoglobulin like receptor A2
PLAC8 Imm Placenta associated 8
CCDC9 Regul Coiled-coil domain containing 9
GLI3 Regul GLI family zinc finger 3
HGF Regul Hepatocyte growth factor
RGS18 Regul Regulator of G protein signaling 18
SFRP4 Regul Secreted frizzled related protein 4
OR6K6 Sig Olfactory receptor family 6 subfamily K member 6
RTP3 Sig Receptor transporter protein 3
VWF UA Von Willebrand factor
Late progression
IGHG3*02 Adap Immunoglobulin heavy constant gamma 3
IGHM Adap Immunoglobulin heavy constant mu
IGHV3-49 Adap Immunoglobulin heavy variable 3–49
IGHV3-72 Adap Immunoglobulin heavy variable 3–72
IGHV3-73 Adap Immunoglobulin heavy variable 3–73
IGHV3-AGQ*02 Adap Immunoglobulin heavy variable 3 AGQ*02
IGJ Adap joining chain of multimeric IgA and IgM
IGKV1-9 Adap immunoglobulin kappa variable 1–9
IGKV1-ABV*02 Adap Immunoglobulin kappa variable 1 ABV*02
IGKV1-ACY*02 Adap Immunoglobulin kappa variable 1 ACY*02
IGKV1z Adap Immunoglobulin kappa variable 1z
IGKV2-ABW*04 Adap Immunoglobulin kappa variable 2 ABW*04
IGKV2S19*01 Adap Immunoglobulin kappa variable 2S19*01
IGKV3-ADU*02 Adap Immunoglobulin kappa variable 3 ADU*02
IGKV4-1 Adap Immunoglobulin kappa variable 4–1
IGLV1-ABB*02 Adap Immunoglobulin lambda variable 1 ABB*02
IGLV1-ACV*02 Adap Immunoglobulin lambda variable 1 ACV*02
IGLV2a Adap Immunoglobulin lambda variable 2a
IGLV2-ABU*02 Adap Immunoglobulin lambda variable 2 ABU*02
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IGLV5-AAX*02 Adap Immunoglobulin lambda variable 5 AAX*02
IGLV7-46 Adap Immunoglobulin lambda variable 7–46
IGLV8-61 Adap Immunoglobulin lambda variable 8–61
KLHL6 Adap Kelch like family member 6
COL4A2 Conn Collagen type IV alpha 2
KRT24 Epi Keratin, type I cytoskeletal 24-like
THBS1 Epi Thrombospondin 1
BANK1 Imm B cell scaffold protein with ankyrin repeats 1
FPR3 Imm Formyl peptide receptor 3
GREM1 Imm Gremlin 1, DAN gamily BMP antagonist
LST1 Imm Leukocyte specific transcript 1
SERPINB5 Imm Serpin family B member 5
TEK Imm TEK receptor tyrosine kinase
CD36 Inflam CD36 molecule (thrombospondin receptor)
CXCR1 Inflam Chemokine (C-X-C motif) receptor 1
PTGS2 Inflam Prostaglandin-endoperoxide synthase 2
TREM1 Inflam Triggering receptor expressed on myeloid cells 1
BCAT1 Metab Branched chain amino acid transaminase 1
DYSF Metab Dysferlin
KYNU Metab Kynureninase-like
SLC2A14 Metab Solute carrier family 2 member 14
SLC15A1 Metab Solute carrier family 15 member 2
SNORD116-17 Regul Small nucleolar RNA, C/D box 116–17
TENT5C Regul Terminal nucelotidyltransferase 5C
ZNF337 Regul Zinc finger protein 337
UTS2B Sig Urotensin 2B
Health versus resolution
IGLV2S9*01 Adap Immunoglobulin lambda variable 2S-9*01
IGHV3-ADR*02 Adap Immunoglobulin heavy variable 3 ADR*02
DRAM1 Conn DNA damage regulated autophagy modulator 1
ESM1 Conn Endothelial cell-specific molecule 1
TFPI Conn Tissue factor pathway inhibitor
MMP1 Conn Matrix metalloproteinase 1
PXDN Conn Peroxidasin
KLK5 Epi Kallikrein related peptidase 5
KRT1 Epi Keratin 1
KRT10 Epi Keratin 10
KRT75 Epi Keratin 75
LCE3C Epi Late cornified envelope 3C
LIPM Epi Lipase Family Member M
ALOX12B Epi Arachidonate 12-lipoxygenase, 12R type
KRT2B Epi Keratin, type II cytoskeletal 2 oral-like
NID1 Epi Nidogen 1
ODAM Epi Odontogenic, ameloblast associated
PRR9 Epi Proline rich 9
SPINK9 Epi Serine peptidase Inhibitor, kazal type 9
CRNN Epi Cornulin
DSC1 Epi Desmocolin 1
SIRPB1 Imm Signal regulatory proten beta 1
SLAMF6 Imm SLAM family member 6
WFDC12 Imm WAP four-disulfide core domain 12
CSF3R Inflam Colony stimulating factor 3 receptor (granulocyte)
CXCL8 Inflam Interleukin 8
CXCL6 Inflam Chemokine (C-X-C motif) ligand 6
HPGD Inflam 15-Hydroxyprostaglandin dehydrogenase
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disease, and finally were uniquely expressed with disease resolution. As was expected there was a large number of 
genes that changed in transition from health to disease, including 900–1400 that were significantly different and 
either increased or decreased with disease. Additionally, there was a large number of genes that were significantly 
different between healthy and resolved tissues, albeit a rather limited number with substantial fold-differences.
A global transcriptomic analysis revealed a panel of genes that were specifically elevated in healthy tissues, as 
well as portfolios of genes that showed unique patterns at 0.5 months (initiation), 1 month (early progression), 
and 3 months (late progression) compared to the other time points. We also noted a panel of genes with levels 
elevated in resolved lesions compared to baseline or disease phases. In order to drill down more deeply within 
the transcriptome to identify the genes of interest, we increased the stringency for inclusion in developing these 
phase specific panels. This approach provided a subset of about 200 + genes that showed differential expression 
at the phases of disease and healthy tissues. Interestingly, at this increased level of stringency we found 53 genes 
in resolved tissues that differed from baseline with 59% showing decreased expression. A second step was to 
explore features of the panels that discriminated disease initiation from other disease phases or resolution. The 
results demonstrated few genes that differed uniquely between initiation and early progression. Thus, while the 
clinical parameters increased significantly from 2 weeks (0.5 months) to 1 month, it appears that changes in 
gene expression occur rapidly and are maintained during this early progression phase of disease. In contrast, 
Gene ID FXN Ontology
AKR1C3 Metab Aldo–Keto Reductase Family 1 Member C3
EGR1 Regul Early growth response 1
FOS Regul Fos proto-oncogene, AP-1 transcription factor subunit
RNU6-1 Regul U6 spliceosome
Table 3.  Identification of altered gene expression in gingival tissues: comparing healthy versus diseased 
gingival tissues (n = 43; in all cases levels of gene expression were elevated in healthy tissues); during initiation/
early progression of disease (n = 45); during late progression of disease (n = 46); and comparing baseline 
healthy tissues to clinically resolved lesions (n = 33). The Adap genes are the human ID designation related to 
antibody nucleotide sequences of the macaque probes. Numerous of the matching macaque sequence Ig gene 
IDs are delineated in Thulliere et al.75. Fxn denotes functional categorization of genes: Adap adaptive immune 
response, Conn connective tissue/bone, Epi epithelium, Imm immune response, Inflam inflammation, Metab 
metabolic, Regul regulatory, Auto autophagy/apoptosis, Sig cellular signaling, UA unassigned to any of these 
functions.
Figure 5.  Principal components analysis of the 89 gingival tissue samples using the profile of discriminatory 
genes identified as disease phase-related. Each point denotes the profile of gene expression for an individual 
gingival tissue sample collected at baseline (healthy), 0.5 months (initiation), 1 month (early progression), 
3 months (late progression), and 5 months (resolution).
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we identified 104 genes that identified tissues at late disease progression versus levels in tissue samples during 
disease initiation with 58% of the expression levels greater in late progression. This suggested the likelihood of 
some specific gene profiles whose function may contribute to the continued progression of the disease lesions. 
Finally, a number of genes (n = 55) were decreased in resolved tissues compared to expression during any phase 
of disease. Most of these represented gene expression levels that were returning back towards baseline levels 
consistent with the improved clinical parameters.
These findings documented the existence of genes that demonstrated significant differences across the biologic 
phases of the disease process and enabled the creation of profiles of “phase-specific” genes. The genes elevated 
in health, but never in diseased tissues were over-represented for biologic pathways of epithelial cell functions, 
metabolism, and inflammation (Table 2). As these gene expression variations represent early disease changes in 
this human-like disease model, potentially a subset of these gene products could be targeted as early biomarkers 
of disease in humans, potentially enabling earlier identification and intervention to minimize tissue damage.
The data also explored the determination if a pattern of genes was also relatively specific for what would be 
considered “early progression” (1 month) in this model related to clear increases in the trajectory of clinical 
parameters of BOP and PPD. Interestingly, a rather broad variation in expression of the various clusters of genes 
was noted during early progression. In the nonhuman primate model, extensive studies of clinical measures have 
demonstrated a general expression of periodontal disease within 1 month post-ligation in nearly all animals 
although the rate differs for individual  animals42–44. Also, a portion of the animals demonstrate clinical measures 
that show minimal increases between 1 and 3 months (early responders), while a subset of the animals clearly 
demonstrate a continued progression of disease, reaching maximum PPD at the 3 month time point, which we 
defined as “late progression”. As such, the gene analysis prediction grouped selected animals at early progression 
as either initiation, early or late progression, suggesting an extent of biologic variation in the population during 
the early transition to progressing destructive disease. This type of temporal variability is likely also reflected 
within the human population based upon clinical measures of gingivitis and progressing periodontitis, albeit little 
Table 4.  Gene clusters used to categorize the gingival samples. The threshold cutoff ratio determined as  Tc for 
the normalized signal.
Gene cluster
I Tc II Tc III Tc IV Tc
TNFRSF19  > 150 ADAM12  > 1200 DYSF  > 400 CDSN  > 1300
ANAX3  > 200 PLAT  > 150 KYNU  > 80 CEACAM8  > 600
SERPINE2  > 400 MIR223  > 400 SLC2A14  > 500 LCE3C  > 200
CD177  > 425 NOX4  > 500 CXCR1  < 500 NID2  > 1500
CSF3R  < 350 BLK  > 150 SERPINB5  > 500 THBS1  > 100
ALOX12B  > 300 KRT1  > 75 KRT24  > 250 COL15A1  > 100
KRT2B  > 100 MUC4  > 800 MZB1  > 175 COL4A1  > 500
NID1  > 50 TLR4  > 350 EGR1  > 65 SERPINE1  > 400
MMP1  > 300 HAS2  > 225 CD36  > 200 TGM2  > 1100
PXDN  < 125 TEK  > 200 PTGS2  > 400 HGF  < 350
CRNN  > 300 CTSL  > 350 LST1  > 400 TREM1  < 750
DSC1  > 300 RUBCNL  > 150 COL4A2  > 300 SELL  > 20
DRAM1  > 60 GREM1  > 450 CLDN10  > 200
ESM1  < 175 FPR3  > 350 SFRP4  > 325
TFPI  < 1000 MZB1  > 1000 SNORD116  > 150
SIRPB1  < 1300 CYP4F3  > 225 TENT5C  > 1700
HPGD  > 350 BANK1  > 150
CXCL8  < 200 BCAT1  > 75
CXCL6  > 100
SLAMF6  > 600
IA Tc IB Tc
CSF3R  < 350 CRNN  < 300
ALOX12B  > 350 DSC1  < 300
KRT2B  > 125 DRAM1  < 50
NID1  > 35 ESM1  > 200
MMP1  > 375 TFPI  < 750
PXDN  > 125 SIRPB1  > 1300
HPGD  < 350
CXCL8  > 250
CXCL6  < 100
SLAMF6  < 700
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is known regarding the biological differences occurring with this disease transition. In contrast, the gene profiling 
analysis identified an array of genes with levels that were expressed uniquely at 3 months (late progression) and 
were able to discriminate this disease phase. These included immune pathways and, of particular note was the 
large array of gene expression changes related to formation and recombination events for antibody molecules. 
Moreover, some genes that were increased at 1 month continued to increase to an even greater extent at 3 months, 
while other members of this late progressing panel were elevated only at this phase of disease. These patterns 
enabled the identification of a set of 67 genes that could be assembled into 4 clusters and used to classify health 
and disease phases. Creating thresholds for individual gene expression, the 4 clusters effectively classified the 
specimens from healthy sites with > 80% accuracy and delineated the initiation and late progression samples at 
72% and 94% accuracy, respectively.
Finally, the data provided insight into fundamental biologic differences between gingival tissues of periodon-
tal health and clinically normal gingiva at sites where the lesion has resolved. In this regard, there is actually 
quite limited data regarding gene expression profiles in human tissues following non-surgical therapy. Beikler 
et al.45 examined a limited subset of gene encompassing inflammatory responses, as well as epithelial, connec-
tive, and endothelial tissues celluar responses. As such, our model in which we mitigate local inciting factors 
similar to scaling and root planing in humans provides some insights into addressing differences in healthy tis-
sues compared to tissues at sites of resolved lesions. As might be expected, there was a limited number of genes 
Figure 6.  Map of response profiles for gene clusters for the 18 samples obtained at each of the timepoints. 
Red denotes sample demonstrated: Cluster I—> 13 genes; Cluster II—> 9 genes; Cluster III—> 7 genes; Cluster 
IV—> 7 genes with signal greater or less than the threshold cutoff normalized signal  (Tc, Table 3). Green denotes 
sample exhibited fewer genes above or below the  Tc. Similar depiction of the distribution of responses to Cluster 
I genes subgrouped into IA and IB. Red denotes IA—> 2 genes and IB—> 3 genes above/below the  Tc (see 
Table 3). Total % denotes proportion of the samples that were positive in the gene expression cluster.
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with expression differences between healthy and resolved gingival tissues representing epithelial biology and 
inflammatory responses. However, using additional threshold levels for expression of Cluster I genes 75–80% 
of the healthy versus resolved specimens were categorized accurately. Thus, the gingival tissues do not appear to 
return to complete biologic health within 60 days of clinical disease resolution. This might suggest that previously 
diseased sites that have been treated and resolved may appear clinically normal; however, they could remain 
biologically programmed for a heightened risk of disease related to a subsequent noxious challenge. Similarly a 
recent clinical study reported that even in well-maintained patients the oral microbiome seems more pathogenic 
than in healthy control sites without previous history of  periodontitis46. This finding also supports a new concept 
related to the recent classification scheme for periodontitis and reinforces the concept that a patient with peri-
odontal disease experience will be always a patient with enhanced periodontal disease risk even after reaching 
clinically healthy conditions.
While this report focused on characterizing the gingival transcriptome in this model of health, disease, and 
resolution, it cannot be ignored that there also occur parallel changes in the oral microbiome with increases in 
pathobionts and a resulting  dysbiosis47 that reflects and/or drives the tissue destructive features of periodon-
titis. Importantly, there exists a reasonable linkage between reported microbiome changes and the features 
of gene expression changes that were identified. P. gingivalis hallmarks these changes by impacting apoptosis 
and autophagy processes allowing it to invade, survive, and disrupt the normal lifecycle of epithelial  cells48,49. 
Additionally, other reports have documented dysregulated inflammatory, protective, and cellular integrity for 
an array of cells induced by numerous oral  bacteria50,51. Related to the array of genes that were altered with 
disease initiation and progression, a number of proposed oral pathogens also have the capacity to translocate to 
deeper tissues and create intraepithelial/mucosal microbial communities. This process would trigger an enhanced 
Table 5.  Targeted biomarkers for periodontal lesion phases reported as diagnostic biomarkers for various 
inflammatory and non-inflammatory diseases.
Cluster Protein Fluid Biologic linkage
I ALOX12B Serum/plasma Diabetes
I CRNN Serum/plasma Epithelial-induced stress protein
I CSF3R Serum/plasma Cancer related gene
I CXCL6 Serum/plasma/urine/saliva Antibacterial/neutrophil
I CXCL8 (IL-8) Serum/plasma/saliva Pancreatic cancer; breast cancer
I ESM1 Serum/saliva (Endocan) CVD, PCOS
I HPGD Serum/plasma/saliva Cancer
I MMP1 Serum/plasma/saliva CVD; arthritis
I NID1 Plasma/saliva Cancer
I PXDN Serum/plasma/saliva Fibrosis
I TFPI Serum/plasma Coagulation
I TNFRSF19 Serum/plasma Cancer
I SERPINE2 Serum Cancer
II TLR4 Serum/plasma/saliva Arthritis, autoimmunity
II ADAM12 Serum/plasma Fibrosis; lung disease
II KRT1 Serum/plasma Cancer
II MIR223 Serum/plasma/saliva Cancer; CVD
II MUC4 Serum/cyst fluid/saliva Cancer
II NOX4 Serum/plasma Inflammation
II PLAT Serum/plasma/saliva CVD
II TEK Serum/plasma Cancer, autoimmune
II HAS2 Serum/plasma/saliva Inflammation; arthritis
III CD36 Serum/plasma Foam cell formation (CVD)
III KYNU Serum/plasma Psoriasis
III GREM1 Serum Inflammation
III FPR3 Serum COPD
IV SERPINE1 Serum/plasma/saliva CVD (PAI-1)
IV CEACAM8 Serum/plasma/saliva Arthritis
IV HGF Serum/plasma/saliva Liver disease; cancer
IV NID2 Serum/plasma/saliva Cancer
IV SELL Plasma Alzheimer’s; schizophrenia
IV SFRP4 Serum/plasma Diabetes
IV THBS1 Serum/saliva Obesity; pregnancy
IV TREM1 Serum/saliva Inflammatory bowel disease
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inflammatory cell infiltrate and resulting microvascularization as a feature of the inflammatory response in 
 disease52. As such, the dysbiotic microbiome, related to an increased burden of individual pathogenic species, 
undermines the normal homeostatic mechanisms of the various gingival cells, with genes in the phase arrays 
from this study consistent with these microbial-induced  changes53.
This model provided us the capacity to develop algorithms of gene expression that enabled phasing disease 
and distinguish between resolved and uninvolved healthy sites. Based upon existing data from cross-sectional 
human gingival  transcriptomes54–57, we can test these gene panels with the human data to potentially enhance 
the homogeneity of the human specimens for disease phases and resolution and identify with more precision 
biomarkers that may be useful in management of the human disease. However, utility of this specific gene 
expression knowledge would be limited for clinical care in humans since routine sampling of gingival tissues for 
targeted gene expression would not be feasible. Nevertheless, many of these genes would be predicted to result in 
secreted translated biomolecules that would be expected to be present in the gingival crevicular fluid and could 
even be detected in saliva to potentially discriminate health, disease phases, and resolved lesions. Importantly, 
as shown in Table 5 many of these biomolecules have already been evaluated and associate with many chronic 
inflammatory conditions. Based upon this unbiased approach to identification of potential biomarkers, panels 
of a finite number of gene products could be evaluated in humans to enable a better understanding of molecular 
mechanisms and development of targeted therapies with more precision.
Methods
Animal model of periodontitis. Rhesus monkeys (Macaca mulatta) (n = 18; 10 females and 8 males) aged 
12–23 years housed at the Caribbean Primate Research Center at Sabana Seca, Puerto  Rico58–60. The nonhuman 
primates were typically fed a 20% protein, 5% fat, and 10% fiber commercial monkey diet (diet 8773, Teklad NIB 
primate diet modified: Harlan Teklad, Madison, WI). The diet was supplemented with fruits and vegetables, and 
water was provided ad libitum in an enclosed corral setting.
All experimental protocols were approved by the Institutional Animal Care and Use Committees (IACUC) 
of the University of Puerto Rico and University of Kentucky. The methods were carried out in accordance with 
all relevant regulations for the use of nonhuman primates following ARRIVE guidelines. Anesthetized animals 
were examined by a single investigator using a Maryland probe on the facial aspect of the teeth, 2 proximal sites 
per tooth (mesio- and disto-buccal), excluding the canines and 3rd molars. The clinical examination included 
probing pocket depth (PD), and bleeding on probing (BOP; 0–5 scale)16. Periodontal health was defined by mean 
Pocket Depth (PD) ≤ 3.0 mm and mean Bleeding on Probing (BOP) ≤ 1 (0–5 scale) in a full mouth examination 
excluding 3rd molars and  canines61. Determination of periodontal disease at the sampled site was documented 
by assessment of the presence of BOP and probing pocket depth of > 4 mm as we have described previously.
Ligature-induced periodontitis was induced in each of the animals at 1st premolar and 1st and 2nd molars 
in all 4 quadrants following a baseline sampling of gingival tissue from a healthy site. Further, clinical evalua-
tion for ligated sites was obtained and a buccal gingival papilla from each animal was taken using a standard 
gingivectomy technique at 2 weeks (initiation of disease), and 1 month and 3 months (progression of disease). 
Then, ligatures were removed after sampling at 3 months and samples taken 2 months later (resolution)28,62,63. 
Since the removal of the ligature eliminates the local noxious mechanical challenge and decreases the microbial 
burden accumulating at the tooth, this process is similar to nonsurgical periodontal therapy in humans. Previ-
ously published histological studies have documented the significant increase in inflammatory cell infiltrate in 
the ligated tissues consistent with the clinical features of inflammation and increased probing pocket  depth64,65.
Gingival tissue sample collection and mRNA analysis. Gingival tissue samples of healthy of dis-
ease sites were surgically collected as we have described previously providing buccal gingival samples from 
either healthy or periodontitis-affected tissue from the premolar/molar maxillary region of each animal using a 
standard gingivectomy  technique58,66,67. Samples were maintained frozen at − 80 °C in RNAlater solution until 
RNA preparation for microarray analysis. Total RNA was isolated from tissues using TRizol reagent (Invitrogen, 
Carlsbad, CA, USA). After cleaning with Qiagen RNeasy mini kit (Qiagen, Valencia, CA, USA), all microarray 
RNA expression analyses were done at the University of Kentucky Microarray facility. Tissue RNA samples were 
submitted to the UK Microarray Core Facility and RNA quality was assessed with an Agilent 2100 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA, USA). Reverse transcription of equal amounts of RNA from each sam-
ple was performed, followed by hybridization to the GeneChip Rhesus Gene 1.0 ST Array (Affymetrix, Santa 
Clara, CA, USA) similar to methods we have described  previously59,67,68. We have also previously published 
multiple reports examining an array of biologic pathways and included validation of numerous genes between 
the microarray and qPCR  results61,64,65,69–71. A summary of these results is displayed in Supplemental Fig. S2 that 
demonstrates, as we have noted previously, a significant relationship between the microarray and qPCR analyses 
regarding directional changes, albeit the qPCR tended to provide a somewhat broader range in the differential 
expression changes.
Data analysis. The expression intensities for genes across the 18 samples were estimated using the Robust 
Multi-array Average (RMA) algorithm with probe-level quintile normalization, as implemented in the Partek 
Genomics Suite software version 6.6 (Partek, St. Louis, MO). The different groups were initially compared using 
one-way ANOVA. For genes that had significant mean differences, two sample t-tests were used to investigate 
differences. The data has been uploaded into the ArrayExpress data base (www. ebi. ac. uk) under accession num-
ber: E-MTAB-1977. A number of Affymetrix probes with unique expression profiles in the samples had not 
been annotated. For these, we used the Ensembl ID (EMBL-EBI) to extract out the nucleotide base sequence for 
the probe from the Affymetrix Exon/Gene (http:// www. affym etrix. com/ analy sis/ index. affx#1_2) website. This 
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sequence was then searched in Blast (https:// blast. ncbi. nlm. nih. gov/ Blast. cgi) and the highest percent identity 
for M. mulatta selected.
Normalized expression profiles of genes that were differentially expressed at least across one of the time points 
Baseline, 2 weeks, 1 Month, 3 Months, 5 Months with the remaining time points as background were used as 
input to Principal component analysis (PCA)72–74. The first and second dominant eigen values explained ~ 62% 
of the variance in the given data and two-dimensional projection of the gene expression profile revealed inherent 
clustering of the time points.
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